Abstract
The low regeneration potential of the central nervous system (CNS) represents a challenge for the development of new therapeutic strategies. Mesenchymal stem cells (MSCs) have been proposed as a possible therapeutic tool for CNS disorders. In addition to their differentiation potential, it is well accepted nowadays that their beneficial actions can also be mediated by their secretome. Indeed, it was already demonstrated, both in vitro and in vivo, that MSCs are able to secrete a broad range of neuroregulatory factors that promote an increase in neurogenesis, inhibition of apoptosis and glial scar formation, immunomodulation, angiogenesis, neuronal and glial cell survival, as well as relevant neuroprotective actions on different pathophysiological contexts. Considering their protective action in lesioned sites, MSCs’ secretome might also improve the integration of local progenitor cells in neuroregeneration processes, opening a door for their future use as therapeutical strategies in human clinical trials. Thus, in this review we analyze the current understanding of MSCs secretome as a new paradigm for the treatment of CNS neurodegenerative diseases.
Similar content being viewed by others
References
Gogel S, Gubernator M, Minger SL (2011) Progress and prospects: stem cells and neurological diseases. Gene Ther 18(1):1–6
Lindvall O, Kokaia Z (2010) Stem cells in human neurodegenerative disorders—time for clinical translation? J Clin Invest 120(1):29–40
Lindvall O, Barker RA, Brustle O et al (2012) Clinical translation of stem cells in neurodegenerative disorders. Cell Stem Cell 10(2):151–155
Becerra J, Santos-Ruiz L, Andrades JA et al (2011) The stem cell niche should be a key issue for cell therapy in regenerative medicine. Stem Cell Rev 7(2):248–255
Chen FM, Wu LA, Zhang M et al (2011) Homing of endogenous stem/progenitor cells for in situ tissue regeneration: promises, strategies, and translational perspectives. Biomaterials 32(12):3189–3209
Chen FM, Zhao YM, Jin Y et al (2012) Prospects for translational regenerative medicine. Biotechnol Adv 30(3):658–672
Kassem M, Kristiansen M, Abdallah BM (2004) Mesenchymal stem cells: cell biology and potential use in therapy. Basic Clin Pharmacol Toxicol 95(5):209–214
Wang S, Qu X, Zhao RC (2011) Mesenchymal stem cells hold promise for regenerative medicine. Front Med 5(4):372–378
Uccelli A, Benvenuto F, Laroni A et al (2011) Neuroprotective features of mesenchymal stem cells. Best Pract Res Clin Haematol 24(1):59–64
Uccelli A, Laroni A, Freedman MS (2011) Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 10(7):649–656
Dominici M, Le Blanc K, Mueller I et al (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315–317
Friedenstein AJ, Deriglasova UF, Kulagina NN et al (1974) Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 2(2):83–92
Zuk PA, Zuk M, Ashjian P et al (2002) Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 13(12):4279–4295
Zuk PA, Zuk M, Mizuno H et al (2001) Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 7(2):211–228
Gronthos S, Mankani M, Brahim J et al (2000) Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci USA 97(25):13625–13630
Shi S, Gronthos S (2003) Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp. J Bone Miner Res 18(4):696–704
Fukuchi Y, Nakajima H, Sugiyama D et al (2004) Human placenta-derived cells have mesenchymal stem/progenitor cell potential. Stem Cells 22(5):649–658
Abumaree MH, Al Jumah M, Kalionis B et al. (2012) Phenotypic and functional characterization of mesenchymal stem cells from chorionic villi of human term placenta. Stem Cell Rev 9(1):16–31
Erices A, Conget P, Minguell JJ (2000) Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 109(1):235–242
Wang HS, Hung SC, Peng ST et al (2004) Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. Stem Cells 22(7):1330–1337
Weiss ML, Troyer DL (2006) Stem cells in the umbilical cord. Stem Cell Rev 2(2):155–162
Paul G, Ozen I, Christophersen NS et al (2012) The adult human brain harbors multipotent perivascular mesenchymal stem cells. PLoS One 7(4):e35577
Chamberlain G, Fox J, Ashton B et al (2007) Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 25(11):2739–2749
Meirelles Lda S, Fontes AM, Covas DT et al (2009) Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 20(5–6):419–427
Phinney DG (2007) Biochemical heterogeneity of mesenchymal stem cell populations: clues to their therapeutic efficacy. Cell Cycle 6(23):2884–2889
Phinney DG, Prockop DJ (2007) Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair–current views. Stem Cells 25(11):2896–2902
Kolf CM, Cho E, Tuan RS (2007) Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. Arthritis Res Ther 9(1):204
Mitchell KE, Weiss ML, Mitchell BM et al (2003) Matrix cells from Wharton’s jelly form neurons and glia. Stem Cells 21(1):50–60
Alaminos M, Perez-Kohler B, Garzon I et al (2010) Transdifferentiation potentiality of human Wharton’s jelly stem cells towards vascular endothelial cells. J Cell Physiol 223(3):640–647
Liqing Y, Jia G, Jiqing C et al (2011) Directed differentiation of motor neuron cell-like cells from human adipose-derived stem cells in vitro. NeuroReport 22(8):370–373
Baer PC, Geiger H (2012) Adipose-derived mesenchymal stromal/stem cells: tissue localization, characterization, and heterogeneity. Stem Cells Int 2012:812693
Maltman DJ, Hardy SA, Przyborski SA (2011) Role of mesenchymal stem cells in neurogenesis and nervous system repair. Neurochem Int 59(3):347–356
Meyerrose T, Olson S, Pontow S et al (2010) Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors. Adv Drug Deliv Rev 62(12):1167–1174
Skalnikova H, Motlik J, Gadher SJ et al (2011) Mapping of the secretome of primary isolates of mammalian cells, stem cells and derived cell lines. Proteomics 11(4):691–708
Chen L, Tredget EE, Wu PY et al (2008) Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 3(4):e1886
Block GJ, Ohkouchi S, Fung F et al (2009) Multipotent stromal cells are activated to reduce apoptosis in part by upregulation and secretion of stanniocalcin-1. Stem Cells 27(3):670–681
Wagner J, Kean T, Young R et al (2009) Optimizing mesenchymal stem cell-based therapeutics. Curr Opin Biotechnol 20(5):531–536
Baglio SR, Pegtel DM, Baldini N (2012) Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy. Front Physiol 3:359
Valadi H, Ekstrom K, Bossios A et al (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9(6):654–659
Pegtel DM, Cosmopoulos K, Thorley-Lawson DA et al (2010) Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci USA 107(14):6328–6333
Lai RC, Arslan F, Lee MM et al (2010) Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res 4(3):214–222
Chen TS, Arslan F, Yin Y et al (2011) Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs. J Transl Med 9:47
Shi Y, Hu G, Su J et al (2010) Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res 20(5):510–518
Kode JA, Mukherjee S, Joglekar MV et al (2009) Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration. Cytotherapy 11(4):377–391
Puissant B, Barreau C, Bourin P et al (2005) Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol 129(1):118–129
Lanza C, Morando S, Voci A et al (2009) Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. J Neurochem 110(5):1674–1684
Caplan AI, Dennis JE (2006) Mesenchymal stem cells as trophic mediators. J Cell Biochem 98(5):1076–1084
Crigler L, Robey RC, Asawachaicharn A et al (2006) Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol 198(1):54–64
Nakano N, Nakai Y, Seo TB et al (2010) Characterization of conditioned medium of cultured bone marrow stromal cells. Neurosci Lett 483(1):57–61
Wilkins A, Kemp K, Ginty M et al (2009) Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Res 3(1):63–70
Ribeiro CA, Salgado AJ, Fraga JS et al (2011) The secretome of bone marrow mesenchymal stem cells—conditioned media varies with time and drives a distinct effect on mature neurons and glial cells (primary cultures). J Tissue Eng Regen Med 5(8):668–672
Cova L, Armentero MT, Zennaro E et al (2010) Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson’s disease. Brain Res 1311:12–27
Nicaise C, Mitrecic D, Pochet R (2011) Brain and spinal cord affected by amyotrophic lateral sclerosis induce differential growth factors expression in rat mesenchymal and neural stem cells. Neuropathol Appl Neurobiol 37(2):179–188
Rehman J, Traktuev D, Li J et al (2004) Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 109(10):1292–1298
Salgado AJ, Reis RL, Sousa NJ et al (2010) Adipose tissue derived stem cells secretome: soluble factors and their roles in regenerative medicine. Curr Stem Cell Res Ther 5(2):103–110
Lu S, Lu C, Han Q et al (2011) Adipose-derived mesenchymal stem cells protect PC12 cells from glutamate excitotoxicity-induced apoptosis by upregulation of XIAP through PI3-K/Akt activation. Toxicology 279(1–3):189–195
Tan B, Luan Z, Wei X et al (2011) AMP-activated kinase mediates adipose stem cell-stimulated neuritogenesis of PC12 cells. Neuroscience 181:40–47
Wei X, Du Z, Zhao L et al (2009) IFATS collection: the conditioned media of adipose stromal cells protect against hypoxia-ischemia-induced brain damage in neonatal rats. Stem Cells 27(2):478–488
Ribeiro CA, Fraga JS, Graos M et al (2012) The secretome of stem cells isolated from the adipose tissue and Wharton jelly acts differently on central nervous system derived cell populations. Stem Cell Res Ther 3(3):18
Arboleda D, Forostyak S, Jendelova P et al (2011) Transplantation of predifferentiated adipose-derived stromal cells for the treatment of spinal cord injury. Cell Mol Neurobiol 31(7):1113–1122
Egashira Y, Sugitani S, Suzuki Y et al (2012) The conditioned medium of murine and human adipose-derived stem cells exerts neuroprotective effects against experimental stroke model. Brain Res 1461:87–95
Lopatina T, Kalinina N, Karagyaur M et al (2011) Adipose-derived stem cells stimulate regeneration of peripheral nerves: BDNF secreted by these cells promotes nerve healing and axon growth de novo. PLoS One 6(3):e17899
Koh SH, Kim KS, Choi MR et al (2008) Implantation of human umbilical cord-derived mesenchymal stem cells as a neuroprotective therapy for ischemic stroke in rats. Brain Res 1229:233–248
Salgado AJ, Fraga JS, Mesquita AR et al (2010) Role of human umbilical cord mesenchymal progenitors conditioned media in neuronal/glial cell densities, viability, and proliferation. Stem Cells Dev 19(7):1067–1074
Ding DC, Shyu WC, Chiang MF et al (2007) Enhancement of neuroplasticity through upregulation of beta1-integrin in human umbilical cord-derived stromal cell implanted stroke model. Neurobiol Dis 27(3):339–353
Abe K, Yamashita T, Takizawa S et al (2012) Stem cell therapy for cerebral ischemia: from basic science to clinical applications. J Cereb Blood Flow Metab 32(7):1317–1331
Pal R, Gopinath C, Rao NM et al (2010) Functional recovery after transplantation of bone marrow-derived human mesenchymal stromal cells in a rat model of spinal cord injury. Cytotherapy 12(6):792–806
Kim HJ, Kim HJ, Lee JY et al (2011) Phenotype analysis in patients with early onset Parkinson’s disease with and without parkin mutations. J Neurol 258(12):2260–2267
Chung YC, Ko HW, Bok E et al (2010) The role of neuroinflammation on the pathogenesis of Parkinson’s disease. BMB Rep 43(4):225–232
Anisimov SV (2009) Cell-based therapeutic approaches for Parkinson’s disease: progress and perspectives. Rev Neurosci 20(5–6):347–381
Singh N, Pillay V, Choonara YE (2007) Advances in the treatment of Parkinson’s disease. Prog Neurobiol 81(1):29–44
Muller T, Hefter H, Hueber R et al (2004) Is levodopa toxic? J Neurol 251(Suppl 6):VI/44–VI/46
Muller T, Renger K, Kuhn W (2004) Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch Neurol 61(5):657–660
Weiner WJ (2006) Advances in the diagnosis, treatment, and understanding of Parkinson’s disease and parkinsonism. Rev Neurol Dis 3(4):191–194
Lindvall O, Brundin P, Widner H et al (1990) Grafts of fetal dopamine neurons survive and improve motor function in Parkinson’s disease. Science 247(4942):574–577
Lindvall O, Rehncrona S, Brundin P et al (1989) Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson’s disease. A detailed account of methodology and a 6-month follow-up. Arch Neurol 46(6):615–631
Lindvall O, Widner H, Rehncrona S et al (1992) Transplantation of fetal dopamine neurons in Parkinson’s disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol 31(2):155–165
Sawle GV, Bloomfield PM, Bjorklund A et al (1992) Transplantation of fetal dopamine neurons in Parkinson’s disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants. Ann Neurol 31(2):166–173
Azari MF, Mathias L, Ozturk E et al (2010) Mesenchymal stem cells for treatment of CNS injury. Curr Neuropharmacol 8(4):316–323
Wang Y, Chen S, Yang D et al (2007) Stem cell transplantation: a promising therapy for Parkinson’s disease. J Neuroimmune Pharmacol 2(3):243–250
Bouchez G, Sensebe L, Vourc’h P et al (2008) Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson’s disease. Neurochem Int 52(7):1332–1342
Levy YS, Bahat-Stroomza M, Barzilay R et al (2008) Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson’s disease. Cytotherapy 10(4):340–352
Jin GZ, Cho SJ, Lee YS et al (2010) Intrastriatal grafts of mesenchymal stem cells in adult intact rats can elevate tyrosine hydroxylase expression and dopamine levels. Cell Biol Int 34(1):135–140
McCoy MK, Martinez TN, Ruhn KA et al (2008) Autologous transplants of Adipose-Derived Adult Stromal (ADAS) cells afford dopaminergic neuroprotection in a model of Parkinson’s disease. Exp Neurol 210(1):14–29
Fu YS, Cheng YC, Lin MY et al (2006) Conversion of human umbilical cord mesenchymal stem cells in Wharton’s jelly to dopaminergic neurons in vitro: potential therapeutic application for Parkinsonism. Stem Cells 24(1):115–124
Kan I, Ben-Zur T, Barhum Y et al (2007) Dopaminergic differentiation of human mesenchymal stem cells—utilization of bioassay for tyrosine hydroxylase expression. Neurosci Lett 419(1):28–33
Chao YX, He BP, Tay SS (2009) Mesenchymal stem cell transplantation attenuates blood brain barrier damage and neuroinflammation and protects dopaminergic neurons against MPTP toxicity in the substantia nigra in a model of Parkinson’s disease. J Neuroimmunol 216(1–2):39–50
Thomas MG, Stone L, Evill L et al (2011) Bone marrow stromal cells as replacement cells for Parkinson’s disease: generation of an anatomical but not functional neuronal phenotype. Transl Res 157(2):56–63
Wang F, Yasuhara T, Shingo T et al (2010) Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1alpha. BMC Neurosci 11:52
Weiss ML, Medicetty S, Bledsoe AR et al (2006) Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson’s disease. Stem Cells 24(3):781–792
Sadan O, Bahat-Stromza M, Barhum Y et al (2009) Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease. Stem Cells Dev 18(8):1179–1190
Sadan O, Shemesh N, Cohen Y et al (2009) Adult neurotrophic factor-secreting stem cells: a potential novel therapy for neurodegenerative diseases. Isr Med Assoc J 11(4):201–204
Blandini F, Cova L, Armentero MT et al (2010) Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat. Cell Transplant 19(2):203–217
Olanow CW (2008) Levodopa/dopamine replacement strategies in Parkinson’s disease–future directions. Mov Disord 23(Suppl 3):S613–S622
Moloney TC, Rooney GE, Barry FP et al (2010) Potential of rat bone marrow-derived mesenchymal stem cells as vehicles for delivery of neurotrophins to the Parkinsonian rat brain. Brain Res 1359:33–43
Mortazavi MM, Verma K, Tubbs RS et al (2011) Cellular and paracellular transplants for spinal cord injury: a review of the literature. Childs Nerv Syst 27(2):237–243
Watson RA, Yeung TM (2011) What is the potential of oligodendrocyte progenitor cells to successfully treat human spinal cord injury? BMC Neurol 11:113
Rabchevsky AG, Patel SP, Springer JE (2011) Pharmacological interventions for spinal cord injury: where do we stand? How might we step forward? Pharmacol Ther 132(1):15–29
Shang AJ, Hong SQ, Xu Q et al (2011) NT-3-secreting human umbilical cord mesenchymal stromal cell transplantation for the treatment of acute spinal cord injury in rats. Brain Res 1391:102–113
Zurita M, Vaquero J (2006) Bone marrow stromal cells can achieve cure of chronic paraplegic rats: functional and morphological outcome one year after transplantation. Neurosci Lett 402(1–2):51–56
Ide C, Nakai Y, Nakano N et al (2010) Bone marrow stromal cell transplantation for treatment of sub-acute spinal cord injury in the rat. Brain Res 1332:32–47
Yang CC, Shih YH, Ko MH et al (2008) Transplantation of human umbilical mesenchymal stem cells from Wharton’s jelly after complete transection of the rat spinal cord. PLoS One 3(10):e3336
Vaquero J, Zurita M (2009) Bone marrow stromal cells for spinal cord repair: a challenge for contemporary neurobiology. Histol Histopathol 24(1):107–116
Wright KT, El Masri W, Osman A et al (2011) Concise review: bone marrow for the treatment of spinal cord injury: mechanisms and clinical applications. Stem Cells 29(2):169–178
Wright KT, El Masri W, Osman A et al (2007) Bone marrow stromal cells stimulate neurite outgrowth over neural proteoglycans (CSPG), myelin associated glycoprotein and Nogo-A. Biochem Biophys Res Commun 354(2):559–566
Lu P, Jones LL, Tuszynski MH (2005) BDNF-expressing marrow stromal cells support extensive axonal growth at sites of spinal cord injury. Exp Neurol 191(2):344–360
Neuhuber B, Timothy Hilmes B, Shumsky JS et al (2005) Axon growth and recovery of function supported by human bone marrow stromal cells in the injured spinal cord exhibit donor variations. Brain Res 1035(1):73–85
Gu W, Zhang F, Xue Q et al (2010) Transplantation of bone marrow mesenchymal stem cells reduces lesion volume and induces axonal regrowth of injured spinal cord. Neuropathology 30(3):205–217
Park HW, Lim MJ, Jung H et al (2010) Human mesenchymal stem cell-derived Schwann cell-like cells exhibit neurotrophic effects, via distinct growth factor production, in a model of spinal cord injury. Glia 58(9):1118–1132
Zhang L, Zhang HT, Hong SQ et al (2009) Cografted Wharton’s jelly cells-derived neurospheres and BDNF promote functional recovery after rat spinal cord transection. Neurochem Res 34(11):2030–2039
Kim KN, Oh SH, Lee KH et al (2006) Effect of human mesenchymal stem cell transplantation combined with growth factor infusion in the repair of injured spinal cord. Acta Neurochir Suppl 99:133–136
Karamouzian S, Nematollahi-Mahani SN, Nakhaee N et al (2012) Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients. Clin Neurol Neurosurg 114(7):935–939
Saito F, Nakatani T, Iwase M et al (2008) Spinal cord injury treatment with intrathecal autologous bone marrow stromal cell transplantation: the first clinical trial case report. J Trauma 64(1):53–59
Saito F, Nakatani T, Iwase M et al (2012) Administration of cultured autologous bone marrow stromal cells into cerebrospinal fluid in spinal injury patients: a pilot study. Restor Neurol Neurosci 30(2):127–136
Hawryluk GW, Mothe A, Wang J et al (2012) An in vivo characterization of trophic factor production following neural precursor cell or bone marrow stromal cell transplantation for spinal cord injury. Stem Cells Dev 21(12):2222–2238
Fehlings MG, Vawda R (2011) Cellular treatments for spinal cord injury: the time is right for clinical trials. Neurotherapeutics 8(4):704–720
Yazdani SO, Pedram M, Hafizi M et al (2012) A comparison between neurally induced bone marrow derived mesenchymal stem cells and olfactory ensheathing glial cells to repair spinal cord injuries in rat. Tissue Cell 44(4):205–213
Lindvall O, Bjorklund A (2004) Cell replacement therapy: helping the brain to repair itself. NeuroRx 1(4):379–381
Ahmad M, Graham SH (2010) Inflammation after stroke: mechanisms and therapeutic approaches. Transl Stroke Res 1(2):74–84
Shafi N, Kasner SE (2011) Treatment of acute ischemic stroke: beyond thrombolysis and supportive care. Neurotherapeutics 8(3):425–433
Locatelli F, Bersano A, Ballaio E et al (2009) Stem cell therapy in stroke. Cell Mol Life Sci 66(5):757–772
Komatsu K, Honmou O, Suzuki J et al (2010) Therapeutic time window of mesenchymal stem cells derived from bone marrow after cerebral ischemia. Brain Res 1334:84–92
Keimpema E, Fokkens MR, Nagy Z et al (2009) Early transient presence of implanted bone marrow stem cells reduces lesion size after cerebral ischaemia in adult rats. Neuropathol Appl Neurobiol 35(1):89–102
Zheng W, Honmou O, Miyata K et al (2010) Therapeutic benefits of human mesenchymal stem cells derived from bone marrow after global cerebral ischemia. Brain Res 1310:8–16
Kurozumi K, Nakamura K, Tamiya T et al (2005) Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. Mol Ther 11(1):96–104
Wang Y, Deng Y, Zhou GQ (2008) SDF-1alpha/CXCR4-mediated migration of systemically transplanted bone marrow stromal cells towards ischemic brain lesion in a rat model. Brain Res 1195:104–112
Wakabayashi K, Nagai A, Sheikh AM et al (2010) Transplantation of human mesenchymal stem cells promotes functional improvement and increased expression of neurotrophic factors in a rat focal cerebral ischemia model. J Neurosci Res 88(5):1017–1025
Leu S, Lin YC, Yuen CM et al (2010) Adipose-derived mesenchymal stem cells markedly attenuate brain infarct size and improve neurological function in rats. J Transl Med 8:63
Tang YL, Zhao Q, Qin X et al (2005) Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann Thorac Surg 80(1):229–236 discussion 236-7
Banas A, Teratani T, Yamamoto Y et al (2008) IFATS collection: in vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury. Stem Cells 26(10):2705–2712
Chen JR, Cheng GY, Sheu CC et al (2008) Transplanted bone marrow stromal cells migrate, differentiate and improve motor function in rats with experimentally induced cerebral stroke. J Anat 213(3):249–258
Bang OY, Lee JS, Lee PH et al (2005) Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 57(6):874–882
Lee JS, Hong JM, Moon GJ et al (2010) A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 28(6):1099–1106
Roh JK, Jung KH, Chu K (2008) Adult stem cell transplantation in stroke: its limitations and prospects. Curr Stem Cell Res Ther 3(3):185–196
Lanfranconi S, Locatelli F, Corti S et al (2011) Growth factors in ischemic stroke. J Cell Mol Med 15(8):1645–1687
Bonfield TL, Nolan Koloze MT, Lennon DP et al (2010) Defining human mesenchymal stem cell efficacy in vivo. J Inflamm (Lond) 7:51
Joyce N, Annett G, Wirthlin L et al (2010) Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen Med 5(6):933–946
Momin EN, Mohyeldin A, Zaidi HA et al (2010) Mesenchymal stem cells: new approaches for the treatment of neurological diseases. Curr Stem Cell Res Ther 5(4):326–344
Lee PH, Park HJ (2009) Bone marrow-derived mesenchymal stem cell therapy as a candidate disease-modifying strategy in Parkinson’s disease and multiple system atrophy. J Clin Neurol 5(1):1–10
Roobrouck VD, Clavel C, Jacobs SA et al (2011) Differentiation potential of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cells reflected in their transcriptome and partially influenced by the culture conditions. Stem Cells 29(5):871–882
Ranganath SH, Levy O, Inamdar MS et al (2012) Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 10(3):244–258
Dharmasaroja P (2009) Bone marrow-derived mesenchymal stem cells for the treatment of ischemic stroke. J Clin Neurosci 16(1):12–20
Liu Z, Li Z, Zhang X et al (2008) Contralesional axonal remodeling of the corticospinal system in adult rats after stroke and bone marrow stromal cell treatment. Stroke 39(9):2571–2577
Choi YJ, Li WY, Moon GJ et al (2010) Enhancing trophic support of mesenchymal stem cells by ex vivo treatment with trophic factors. J Neurol Sci 298(1–2):28–34
Li WY, Choi WJ, Lee PH et al (2008) Mesenchymal stem cells for ischemic stroke: changes in effects after ex vivo culturing. Cell Transplant 17(9):1045–1059
Rivera FJ, Siebzehnrubi FA, Kandasamy M et al (2009) Mesenchymal stem cells promote oligodendroglial differentiation in hippocampal slice cultures. Cell Physiol Biochem 24(3–4):317–324
English K, French A, Wood KJ (2010) Mesenchymal stromal cells: facilitators of successful transplantation? Cell Stem Cell 7(4):431–442
Acknowledgments
We thank to the Portuguese Foundation for Science and Technology (FCT) for: Ciência 2007 program (A.J. Salgado), Grant PTDC/SAU-BMA/114059/2009 and, pre-doctoral fellowships to F.G. Teixeira (SFRH/BD/69637/2010) and Miguel Carvalho (SFRH/BD/51061/2010).
Author information
Authors and Affiliations
Corresponding author
Additional information
F. G. Teixeira and M. M. Carvalho contributed equally to this work.
Rights and permissions
About this article
Cite this article
Teixeira, F.G., Carvalho, M.M., Sousa, N. et al. Mesenchymal stem cells secretome: a new paradigm for central nervous system regeneration?. Cell. Mol. Life Sci. 70, 3871–3882 (2013). https://doi.org/10.1007/s00018-013-1290-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-013-1290-8